Nouvelle initiative, lancée à l’Université d'Aarhus (Danemark) pour reproduire les avantages du jeûne et/ou de l’exercice pour la santé, à l’aide d’un simple médicament. Initiative qui peut sembler su ...

Près de 8 millions de femmes sont atteintes d'un cancer du sein dans le monde et 33 à 44 % souffrent de douleurs lymphatiques ...

Si le Tai Chi a déjà démontré de nombreux bénéfices pour la santé, cette fois, c’est contre l’insomnie que cette équipe de l'Université de Californie Los Angeles (UCLA Health) documente ses avantages.

Walter E. Washington Convention Center, Washington, D.C.

About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

Glass House achieved record setting results for over 10 key metrics, including consolidated revenue and gross profit, wholesale biomass revenue, retail revenue, biomass production and cultivation cost ...

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...

Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for ...

Revenue in the third quarter of 2024 was $8.8 million (-1% YOY) vs. $8.9 million in the third quarter of 2023 “The 2% year-over-year increase in revenue per XTRAC ® system in the third quarter of 2024 ...

On July 21, 2023, AEON completed the Merger with AEON Biopharma Sub, Inc. (“Old AEON”), with Old AEON surviving the merger as a wholly-owned subsidiary of the Company, the accounting acquirer. The ...

R&D expense for the third quarter of 2024 was $7.2 million, compared to $7.3 million for the third quarter of 2023. The decrease of $0.1 million was primarily due to lower clinical trial expenses ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today ...